Zimmer Biomet
998 hedge funds and large institutions have $23.7B invested in Zimmer Biomet in 2021 Q4 according to their latest regulatory filings, with 139 funds opening new positions, 321 increasing their positions, 334 reducing their positions, and 109 closing their positions.
28% more first-time investments, than exits
New positions opened: 139 | Existing positions closed: 109
19% more call options, than puts
Call options by funds: $142M | Put options by funds: $120M
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
2% more funds holding
Funds holding: 982 → 998 (+16)
0.1% more ownership
Funds ownership: 91.89% → 91.99% (+0.1%)
4% less repeat investments, than reductions
Existing positions increased: 321 | Existing positions reduced: 334
13% less capital invested
Capital invested by funds: $27.2B → $23.7B (-$3.57B)
Top Buyers
Top Sellers
ZBH Hedge Fund Activity: Q4 2021 in Review
998 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Zimmer Biomet (ZBH) for Q4 2021, worth a combined $23.7B — down 13% from $27.2B a quarter earlier.
Buyers outnumbered sellers: 139 funds opened new ZBH positions and 109 closed out — a net gain of 30 holders — while 321 added to existing stakes and 334 trimmed.
The largest buyer was Vanguard Group, adding an estimated $439M. The largest seller was Wells Fargo, cutting an estimated $240M.
- 998 institutional investors held Zimmer Biomet (ZBH) as of Q4 2021, up from 982 in Q3 2021.
- Funds reported $23.7B of Zimmer Biomet stock for Q4 2021, down 13% quarter-over-quarter.
- 139 funds opened new Zimmer Biomet positions in Q4 2021 and 109 closed out, a net change of +30 holders.
- The largest Zimmer Biomet buyer in Q4 2021 was Vanguard Group, an estimated $439M added.
- The largest Zimmer Biomet seller in Q4 2021 was Wells Fargo, an estimated $240M sold.
Based on aggregated 13F filings for Q4 2021.